REMEGEN (09995) saw its stock price soar 6.36% during intraday trading on Thursday, following the publication of positive Phase III clinical trial results for its systemic lupus erythematosus (SLE) treatment, Taitasib, in the New England Journal of Medicine (NEJM). The stock reached HKD 96.45, with a substantial trading volume of HKD 205 million.

The clinical trial results, announced via REMEGEN's official WeChat account, demonstrated significant efficacy of Taitasib in treating SLE. The study met its primary endpoint, with 67.1% of patients in the Taitasib group showing marked improvement in disease activity, compared to just 32.7% in the placebo group. This breakthrough positions Taitasib as a potentially transformative B-cell therapy for SLE patients.

REMEGEN's Taitasib, approved for SLE treatment in China in March 2021, is the world's first dual-target biologic targeting both BLyS and APRIL for this indication. Its inclusion in the national health insurance drug list by the end of 2021 further underscores its importance in addressing the unmet needs of SLE patients. With many existing treatments failing to adequately control disease activity, the positive results and prestigious publication of Taitasib's study have likely boosted investor confidence in REMEGEN's potential to capture a significant share of the SLE treatment market.